Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults

Andreas Kuznik, Gaëlle Bégo-Le-Bagousse, Laurent Eckert, Abhijit Gadkari, Eric Simpson, Christopher N. Graham, La Stella Miles, Vera Mastey, Puneet Mahajan, Sean D. Sullivan

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Introduction: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluated, the objective of this analysis was to estimate a value-based price range in which dupilumab would be considered cost-effective compared with supportive care (SC) for treatment of moderate-to-severe AD in an adult population. Methods: A health economic model was developed to evaluate from the US payer perspective the long-term costs and benefits of dupilumab treatment administered every other week (q2w). Dupilumab q2w was compared with SC; robustness of assumptions and results were tested using sensitivity and scenario analyses. Clinical data were derived from the dupilumab LIBERTY AD SOLO trials; healthcare use and cost data were from health insurance claims histories of adult patients with AD. The annual price of maintenance therapy with dupilumab to be considered cost-effective was estimated for decision thresholds of US100,000 and 150,000 per quality-adjusted life-year (QALY) gained. Results: In the base case, the annual maintenance price for dupilumab therapy to be considered cost-effective would be 28,770 at a 100,000 per QALY gained threshold, and 39,940 at a 150,000 threshold. Results were generally robust to parameter variations in one-way and probabilistic sensitivity analyses. Conclusion: Dupilumab q2w compared with SC is cost-effective for the treatment of moderate-to-severe AD in US adults at an annual price of maintenance therapy in the range of 29,000–40,000 at the 100,000–150,000 per QALY thresholds. Funding: Sanofi and Regeneron Pharmaceuticals, Inc.

Original languageEnglish (US)
Pages (from-to)493-505
Number of pages13
JournalDermatology and Therapy
Volume7
Issue number4
DOIs
StatePublished - Dec 1 2017

Fingerprint

Atopic Dermatitis
Cost-Benefit Analysis
Quality-Adjusted Life Years
Therapeutics
Costs and Cost Analysis
Health Care Costs
Economic Models
SAR231893
Pruritus
Health Insurance
Signs and Symptoms
Anxiety
Placebos
Maintenance
Quality of Life
Depression
Health
Pharmaceutical Preparations

Keywords

  • Atopic dermatitis
  • Cost-effectiveness
  • Dupilumab
  • Eczema
  • Health economics
  • Quality-adjusted life-years

ASJC Scopus subject areas

  • Dermatology

Cite this

Kuznik, A., Bégo-Le-Bagousse, G., Eckert, L., Gadkari, A., Simpson, E., Graham, C. N., ... Sullivan, S. D. (2017). Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults. Dermatology and Therapy, 7(4), 493-505. https://doi.org/10.1007/s13555-017-0201-6

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults. / Kuznik, Andreas; Bégo-Le-Bagousse, Gaëlle; Eckert, Laurent; Gadkari, Abhijit; Simpson, Eric; Graham, Christopher N.; Miles, La Stella; Mastey, Vera; Mahajan, Puneet; Sullivan, Sean D.

In: Dermatology and Therapy, Vol. 7, No. 4, 01.12.2017, p. 493-505.

Research output: Contribution to journalArticle

Kuznik, A, Bégo-Le-Bagousse, G, Eckert, L, Gadkari, A, Simpson, E, Graham, CN, Miles, LS, Mastey, V, Mahajan, P & Sullivan, SD 2017, 'Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults', Dermatology and Therapy, vol. 7, no. 4, pp. 493-505. https://doi.org/10.1007/s13555-017-0201-6
Kuznik, Andreas ; Bégo-Le-Bagousse, Gaëlle ; Eckert, Laurent ; Gadkari, Abhijit ; Simpson, Eric ; Graham, Christopher N. ; Miles, La Stella ; Mastey, Vera ; Mahajan, Puneet ; Sullivan, Sean D. / Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults. In: Dermatology and Therapy. 2017 ; Vol. 7, No. 4. pp. 493-505.
@article{4eab1aed861d457ab2d7538029aa31f4,
title = "Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults",
abstract = "Introduction: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluated, the objective of this analysis was to estimate a value-based price range in which dupilumab would be considered cost-effective compared with supportive care (SC) for treatment of moderate-to-severe AD in an adult population. Methods: A health economic model was developed to evaluate from the US payer perspective the long-term costs and benefits of dupilumab treatment administered every other week (q2w). Dupilumab q2w was compared with SC; robustness of assumptions and results were tested using sensitivity and scenario analyses. Clinical data were derived from the dupilumab LIBERTY AD SOLO trials; healthcare use and cost data were from health insurance claims histories of adult patients with AD. The annual price of maintenance therapy with dupilumab to be considered cost-effective was estimated for decision thresholds of US100,000 and 150,000 per quality-adjusted life-year (QALY) gained. Results: In the base case, the annual maintenance price for dupilumab therapy to be considered cost-effective would be 28,770 at a 100,000 per QALY gained threshold, and 39,940 at a 150,000 threshold. Results were generally robust to parameter variations in one-way and probabilistic sensitivity analyses. Conclusion: Dupilumab q2w compared with SC is cost-effective for the treatment of moderate-to-severe AD in US adults at an annual price of maintenance therapy in the range of 29,000–40,000 at the 100,000–150,000 per QALY thresholds. Funding: Sanofi and Regeneron Pharmaceuticals, Inc.",
keywords = "Atopic dermatitis, Cost-effectiveness, Dupilumab, Eczema, Health economics, Quality-adjusted life-years",
author = "Andreas Kuznik and Ga{\"e}lle B{\'e}go-Le-Bagousse and Laurent Eckert and Abhijit Gadkari and Eric Simpson and Graham, {Christopher N.} and Miles, {La Stella} and Vera Mastey and Puneet Mahajan and Sullivan, {Sean D.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s13555-017-0201-6",
language = "English (US)",
volume = "7",
pages = "493--505",
journal = "Dermatology and Therapy",
issn = "2190-9172",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults

AU - Kuznik, Andreas

AU - Bégo-Le-Bagousse, Gaëlle

AU - Eckert, Laurent

AU - Gadkari, Abhijit

AU - Simpson, Eric

AU - Graham, Christopher N.

AU - Miles, La Stella

AU - Mastey, Vera

AU - Mahajan, Puneet

AU - Sullivan, Sean D.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Introduction: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluated, the objective of this analysis was to estimate a value-based price range in which dupilumab would be considered cost-effective compared with supportive care (SC) for treatment of moderate-to-severe AD in an adult population. Methods: A health economic model was developed to evaluate from the US payer perspective the long-term costs and benefits of dupilumab treatment administered every other week (q2w). Dupilumab q2w was compared with SC; robustness of assumptions and results were tested using sensitivity and scenario analyses. Clinical data were derived from the dupilumab LIBERTY AD SOLO trials; healthcare use and cost data were from health insurance claims histories of adult patients with AD. The annual price of maintenance therapy with dupilumab to be considered cost-effective was estimated for decision thresholds of US100,000 and 150,000 per quality-adjusted life-year (QALY) gained. Results: In the base case, the annual maintenance price for dupilumab therapy to be considered cost-effective would be 28,770 at a 100,000 per QALY gained threshold, and 39,940 at a 150,000 threshold. Results were generally robust to parameter variations in one-way and probabilistic sensitivity analyses. Conclusion: Dupilumab q2w compared with SC is cost-effective for the treatment of moderate-to-severe AD in US adults at an annual price of maintenance therapy in the range of 29,000–40,000 at the 100,000–150,000 per QALY thresholds. Funding: Sanofi and Regeneron Pharmaceuticals, Inc.

AB - Introduction: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluated, the objective of this analysis was to estimate a value-based price range in which dupilumab would be considered cost-effective compared with supportive care (SC) for treatment of moderate-to-severe AD in an adult population. Methods: A health economic model was developed to evaluate from the US payer perspective the long-term costs and benefits of dupilumab treatment administered every other week (q2w). Dupilumab q2w was compared with SC; robustness of assumptions and results were tested using sensitivity and scenario analyses. Clinical data were derived from the dupilumab LIBERTY AD SOLO trials; healthcare use and cost data were from health insurance claims histories of adult patients with AD. The annual price of maintenance therapy with dupilumab to be considered cost-effective was estimated for decision thresholds of US100,000 and 150,000 per quality-adjusted life-year (QALY) gained. Results: In the base case, the annual maintenance price for dupilumab therapy to be considered cost-effective would be 28,770 at a 100,000 per QALY gained threshold, and 39,940 at a 150,000 threshold. Results were generally robust to parameter variations in one-way and probabilistic sensitivity analyses. Conclusion: Dupilumab q2w compared with SC is cost-effective for the treatment of moderate-to-severe AD in US adults at an annual price of maintenance therapy in the range of 29,000–40,000 at the 100,000–150,000 per QALY thresholds. Funding: Sanofi and Regeneron Pharmaceuticals, Inc.

KW - Atopic dermatitis

KW - Cost-effectiveness

KW - Dupilumab

KW - Eczema

KW - Health economics

KW - Quality-adjusted life-years

UR - http://www.scopus.com/inward/record.url?scp=85035209828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035209828&partnerID=8YFLogxK

U2 - 10.1007/s13555-017-0201-6

DO - 10.1007/s13555-017-0201-6

M3 - Article

AN - SCOPUS:85035209828

VL - 7

SP - 493

EP - 505

JO - Dermatology and Therapy

JF - Dermatology and Therapy

SN - 2190-9172

IS - 4

ER -